News | July 26, 2021
Glenmark Life Sciences IPO to open on July 27, 2021
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company has reported total income of Rs.45.29 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
Subscribe To Our Newsletter & Stay Updated
